Key facts
- Hurdle (Decision/Risk Analysis)’s last known valuation is $54.3M (Mar 2025).
- It has raised $17.2M; the latest was Later Stage VC ($7.9M) in Mar 2025.
- Notable investors include SOSV, Anthemis, Start Capital, Cola Blanca Investments, Expedite Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Hurdle (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for Hurdle (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hurdle (Decision/Risk Analysis)
Developer of a diagnostic platform designed to facilitate better care, operational optimization, and personalized health interventions. The company's platform utilizes artificial intelligence to analyze diagnostic data and offer personalized and accurate diagnostics, enabling healthcare providers to improve accuracy, efficiency, scalability, and patient care.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2017
- Employees
- 33
- Website
- hurdle.bio/
- Ownership
- Privately Held (backing)
Hurdle (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hurdle (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hurdle (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.